Systemic molecular targets

The term 'Systemic molecular targets' does not refer to a single specific biological molecule, receptor, or enzyme. Instead, it is a general descriptive phrase used in pharmacology and oncology to categorize a wide array of molecular entities—such as receptors, enzymes, and signaling proteins—that are distributed throughout the body and can be modulated by systemic drug delivery, such as oral or intravenous administration [1, 2]. Because it lacks a specific biochemical identity or a unique genetic locus, it cannot be classified into a single molecular family or associated with a specific biological pathway. In clinical literature, this term is often used to group diverse actionable targets like the epidermal growth factor receptor (EGFR), programmed cell death protein 1 (PD-1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) when discussing systemic treatment strategies for diseases like cancer [1, 3]. Consequently, it does not have its own specific interacting drugs, mechanisms of action, or safety profiles, as these properties belong to the individual molecules within the category [2, 4].

Other names

Systemic targetsMolecular targets for systemic therapy

Not applicable; this is a categorical term rather than a specific molecular entity.